Physician profile
John T Jay
NPI 1710415021
$609.30
in general payments reported to CMS, 2019-2025
15 companies · $179 in 2025
The $179 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15.79 · 2020: $14.35 · 2021: $163 · 2023: $22.44 · 2024: $215 · 2025: $179.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $416.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $416.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $123.05 | 2021 | |
| Dendreon Pharmaceuticals LLC | $86.68 | 2024 | Provenge |
| Janssen Pharmaceuticals, INC | $65.63 | 2020-2023 | Xarelto |
| Novo Nordisk INC | $57.71 | 2024-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $56.24 | 2024-2025 | |
| Lilly USA, LLC | $37.09 | 2024-2025 | Mounjaro |
| Antares Pharma, INC. | $32.58 | 2024-2025 | Xyosted |
| Bayer Healthcare Pharmaceuticals INC. | $27.11 | 2025 | |
| Astrazeneca Pharmaceuticals Lp | $26.47 | 2021-2025 | Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.09 | 2024 | Jardiance |
| Glaxosmithkline, LLC. | $18.24 | 2025 | Trelegy Ellipta |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $15.79 | 2019 | |
| Lucid Diagnostics INC. | $14.01 | 2024 | |
| Sanofi-Aventis U.S. LLC | $13.88 | 2025 | |
| Pfizer INC. | $13.73 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Jay listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.